

Biosimilars Market is growing at a CAGR of 23.5% from 2024 to 2030 by Exactitude Consultancy

The Exactitude Consultancy Biosimilars Market Report – Size, Trends, and Forecast 2024-2030

LUTON, BEDFORDSHIRE, UNITED KINGDOM, March 1, 2024 /EINPresswire.com/ -- ****Everything You Need to Know About [Biosimilars](#) everything is Here....!

The Comprehensive study on Biosimilars Market includes historical data as well as share, size, and projection information for the major players, geographies, applications, and product categories for the years 2024 to 2030. The Market study includes comprehensive insights on the competitive environment, description, broad product portfolio of key players, SWOT analysis, and significant business strategy implemented by rivals, revenue, Porters Five Forces Analysis, and sales projections. The report also features an impact analysis of the market dynamics, highlighting the factors currently driving and limiting market growth, and the impact they could have on the short, medium, and long-term outlook. The main goal of the paper is to further illustrate how the latest scenario, the economic slowdown, and war events affect the market for Biosimilars.

“

The demand for biosimilars is steadily increasing due to their cost-effectiveness compared to original biologics, driving growth in the market.”

Exactitude Consultancy

the forecast period. The increasing interest of the individuals in this industry is that the major reason for the expansion of this market.



The Top Key Players profiled in the report:

Novartis, Synthon Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., LG Life Sciences, Celltrion, Biocon, Hospira, Merck Serono, Biogen idec, Inc., Genentech

Recent Development:

February 06, 2023: Sandoz, a Novartis division and a global leader in off-patent (generic and biosimilar) medicines announced that the Food and Drug Administration (FDA), US has accepted its Biologics License Application (BLA) for proposed biosimilar denosumab.

January 24, 2023: Sandoz, a Novartis division announced agreement to acquire leading antifungal agent Mycamine® from Astellas, reinforcing hospital offering and leading Anti-Infectives portfolio.

Click the link to get a free sample copy of the report :

<https://exactitudeconsultancy.com/reports/14506/biosimilars-market/#request-a-sample>

(*If you have any special requirements, please let us know and we will provide you with the report as you wish.)

Biosimilars Market Segmentation:

Biosimilars Market By Product, 2020-2029, (USD Billion)

Monoclonal Antibodies

Infliximab

Trastuzumab

Rituximab

Adalimumab

Others

Insulin

Granulocyte Colony-Stimulating Factor

Erythropoietin

Recombinant Human Growth Hormone

Etanercept

Follitropin

Teriparatide

Interferons

Enoxaparin Sodium

Glucagon

Calcitonin

Biosimilars Market By Indication, 2020-2029, (USD Billion)

Oncology

Inflammatory & Autoimmune Disorders

Chronic Diseases

Blood Disorders

Growth Hormone Deficiency

Infectious Diseases

Others

Based on geography, the global market for Biosimilars and Disruptions has been segmented as follows:

Europe is the largest market share holder worldwide, followed by North America and Asia-Pacific. The impending patent expiration of biologic drugs and the introduction of new biosimilars, the rise in the prevalence of chronic diseases, the appearance of new companies, and early entry into the market are some of the main drivers of growth in these markets and also due to rise in prevalence of cancer, favorable government initiatives, and well-established healthcare infrastructure in the region. However, Asia-Pacific is expected to record significant growth, due to increase in number of hospitals, prevalence of cancer, and high population. The

rising popularity of the biosimilars in the North America and the existence of numerous market players in the region are investing heavily in the research of the biosimilars, that are expected to drive the growth of the market in this region.

Strategic Points Covered in Biosimilars Market Directory:

To study and analyze the global market size (value & volume) by company, key regions/countries, products and application, history data, and forecast to 2030.

To understand the structure of market by identifying its various sub segments.

To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).

Focuses on the key global manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.

To analyze the growth trends, future prospects, and their contribution to the total market.

To project the value and volume of submarkets, with respect to key regions (along with their respective key countries).

To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

To strategically profile the key players and comprehensively analyze their growth strategies.

The report provides insights on the following pointers:

Market Penetration: Comprehensive information on the product portfolios of the top players in the Biosimilars

Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.

Competitive Assessment: In-depth assessment of the Biosimilars market strategies, geographic and business segments of the leading players in the market.

Market Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies.

Market Diversification: Exhaustive information about new products, untapped geographies,

recent developments, and investments in the Biosimilars

Take a look at the full report with detailed TOC here:

<https://exactitudeconsultancy.com/reports/14506/biosimilars-market/>

Some of the key questions scrutinized in the study are:

Which companies are expanding litany of products with the aim to diversify product portfolio?

Which companies have drifted away from their core competencies and how have those impacted the strategic landscape of the Biosimilars market?

Which companies have expanded their horizons by engaging in long-term societal considerations?

Which firms have bucked the pandemic trend and what frameworks they adopted to stay resilient?

What are the marketing programs for some of the recent product launches?

Regional Links:

<https://exactitudeconsultancy.com/ko/reports/14506/biosimilars-market/>

<https://exactitudeconsultancy.com/zh-CN/reports/14506/biosimilars-market/>

<https://exactitudeconsultancy.com/ja/reports/14506/biosimilars-market/>

<https://exactitudeconsultancy.com/fr/reports/14506/biosimilars-market/>

<https://exactitudeconsultancy.com/de/reports/14506/biosimilars-market/>

We offer customization on the Biosimilars market report based on specific client requirements:

20% free customization.

Five Countries can be added as per your choice.

Five Companies can add as per your choice.

Free customization for up to 40 hours.

After-sales support for 1 year from the date of delivery.

Get More: <https://exactitudeconsultancy.com/primary-research/>

Thank you for your interest in the Biosimilars Market research publications; you can also get individual chapters or regional/country report versions such as Germany, France, China, Latin America, GCC, North America, Europe or Asia.....

About Us:

Exactitude Consultancy is a Market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our professional team works hard to fetch the most authentic research reports backed with impeccable data figures which guarantee outstanding results every time for you. So, whether it is the latest report from the researchers or a custom requirement, our team is here to help you in the best possible way.

Contact:

Irfan T

Exactitude Consultancy

+1 704-266-3234

[email us here](#)

Visit us on social media:

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/692566703>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.